<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is a variable, <z:hpo ids='HP_0000006'>autosomal-dominant</z:hpo> disorder of the connective tissue </plain></SENT>
<SENT sid="1" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> serious <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (SCD) can occur </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this prospective study was to reveal underlying risk factors and to prospectively investigate the association between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and SCD in a long-term follow-up </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: 77 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> were included </plain></SENT>
<SENT sid="4" pm="."><plain>At baseline serum N-terminal pro-brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (NT-proBNP), transthoracic echocardiogram, 12-lead resting ECG, signal-averaged ECG (SAECG) and a 24-h Holter ECG with time- and frequency domain analyses were performed </plain></SENT>
<SENT sid="5" pm="."><plain>The primary composite endpoint was defined as SCD, <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT), <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) or arrhythmogenic <z:hpo ids='HP_0001279'>syncope</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The median follow-up (FU) time was 868days </plain></SENT>
<SENT sid="7" pm="."><plain>Among <z:hpo ids='HP_0000001'>all</z:hpo> risk stratification parameters, NT-proBNP remained the exclusive predictor (hazard ratio [HR]: 2.34, 95% confidence interval [CI]: 1.1 to 4.62, p=0.01) for the composite endpoint </plain></SENT>
<SENT sid="8" pm="."><plain>With an optimal cut-off point at 214.3pg/ml NT-proBNP predicted the composite primary endpoint accurately (AUC 0.936, p=0.00046, sensitivity 100%, specificity 79.0%) </plain></SENT>
<SENT sid="9" pm="."><plain>During FU, seven patients of Group 2 (NT-proBNPâ‰¥214.3pg/ml) reached the composite endpoint and 2 of these patients died due to SCD </plain></SENT>
<SENT sid="10" pm="."><plain>In five patients, sustained VT was documented </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with a NT-proBNP&lt;214.3pg/ml (Group 1) experienced no events </plain></SENT>
<SENT sid="12" pm="."><plain>Group 2 patients had a significantly higher risk of experiencing the composite endpoint (logrank-test, p&lt;0.001) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: In contrast to non-invasive electrocardiographic parameter, NT-proBNP independently predicts adverse arrhythmogenic events in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
</text></document>